CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Grant or award Director acquired 44,178 shares (grant or award)
- 4 Grant or award Director acquired 22,089 shares (grant or award)
- 4 Grant or award Director acquired 44,178 shares (grant or award)
- 4 Grant or award Director acquired 22,089 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Shareholder vote results
- 4 Open-market sale EVP of R&D and CMO sold 11,500 shares at $7.40 ($85,092)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- SC TO-C Deal Written Communication Relating to an Issuer
- PRE 14A Proxy Proxy Statement (Preliminary)
- SC 13D/A Stake Beneficial Ownership Report
- 4 Other disposition 10% owner disposed of 22,032,040 shares (other)
- 4/A Other disposition Director disposed of 4,710,120 shares (other)
- 4 Other disposition Director disposed of 4,710,121 shares (other)
- 4 Grant or award EVP of R&D and CMO acquired 237,358 shares (grant or award)
- 4 Derivatives Options or other derivatives
Page 17 of 30 · 587 filings